Entera Bio shares Phase 2 data and Phase 3 design for oral PTH tablet

October 13, 2026 7:01 AM

Entera Bio Ltd. (NASDAQ: ENTX) presented post-hoc Phase 2 data and its Phase 3 study design for EB613, an oral ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found